Paradigm Biopharmaceuticals (ASX:PAR) COGS-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Paradigm Biopharmaceuticals COGS-to-Revenue?

Paradigm Biopharmaceuticals's Cost of Goods Sold for the six months ended in Dec. 2023 was A$0.00 Mil. Its Revenue for the six months ended in Dec. 2023 was A$0.00 Mil.

Paradigm Biopharmaceuticals's COGS to Revenue for the six months ended in Dec. 2023 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Paradigm Biopharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 was N/A%.

Paradigm Biopharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for Paradigm Biopharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Paradigm Biopharmaceuticals COGS-to-Revenue Chart

Paradigm Biopharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

COGS-to-Revenue

Get a 7-Day Free Trial

4.76

1.82

0.40

Paradigm Biopharmaceuticals Semi-Annual Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial												1.56	2.15	1.60	0.26	-

Paradigm Biopharmaceuticals COGS-to-Revenue Calculation

Paradigm Biopharmaceuticals's COGS to Revenue for the fiscal year that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.019	/	0.047
	=	0.40

Paradigm Biopharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

Paradigm Biopharmaceuticals (ASX:PAR) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Paradigm Biopharmaceuticals's Gross Margin % for the six months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Paradigm Biopharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Paradigm Biopharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Paradigm Biopharmaceuticals (ASX:PAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Paradigm Biopharmaceuticals Ltd (ASX:PAR) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

PBIGF:USA

Address

500 Collins Street, Level 15, Melbourne, VIC, AUS, 3000

Website

https://www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Ltd is a biopharmaceutical company that engages in the research and development of therapeutic products for human use in Australia. The firm is engaged in drug repurposing, pentosan polysulphate sodium (PPS) for the lead clinical indication of bone marrow edema, Alphavirus - Ross River virus (RRV) and Chikungunya virus (CHIKV), Mucopolysaccharidosis, and allergic respiratory conditions, including allergic rhinitis (AR) and chronic obstructive pulmonary disease (COPD).